Logo

Dante Labs Software Nabs CE Mark for Interpretation of Whole-Genome Sequencing Data

Jul 14, 2020 | staff reporter

NEW YORK – Dante Labs announced Tuesday its Immensa software received CE-IVD marking for the interpretation of whole-genome sequencing data in a clinical setting at scale.

The software generates personalized reports for pharmacogenomics, rare diseases, predisposition to common diseases, and nutrigenomics, and integrates guidelines from the American College of Medical Genetics, the company said.

It was built using more than 150,000 genomic reports generated by Dante Labs and integrated user feedback. The software takes 30 seconds to generate a report and can scale with demand, the firm said.

Dante Labs CEO Andrea Riposati said in a statement the software will be available commercially to clinics and hospitals in countries accepting the CE mark "in a few weeks."

Filed under

Regulatory News & FDA Approvals
Sequencing
Genomics: Clinical Implementation
CE mark
Europe
rare disease
ACMG
pharmacogenomics
software
whole-genome sequencing
Dante Labs
Breaking News
The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.